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Abstract 
Background: Although fertility preservation (FP) treatment options have increased, the 
existing evidence suggests that many women with cancer do not feel well supported in 
making these decisions, but find them stressful and complex and fail to take up fertility care 
at this crucial time. Whilst existing reviews have all made important contributions to our 
understanding of the FP decision-making process, none of them examine solely and 
specifically these processes for women of reproductive age with a diagnosis of any cancer, 
leaving a gap in the knowledge base. Given the expectation that care is patient-centred, our 
review aims to address this gap which may be of help to those managing patients struggling 
to make difficult decisions in the often brief period before potentially sterilising cancer 
treatment is started.   
Objective and rationale: Underpinning this narrative review was the question “What factors 
hinder the decision-making process for women with any cancer and contemplating FP 
treatment?” Our objectives were to i) assess and summarise this existing literature, ii) identify 
the factors that hinder this decision-making process, iii) explore to what extent these factors 
may differ for women choosing different methods of FP, and iv) make recommendations for 
service delivery and future research. 
Search methods: A systematic search of the medical and social science literature from the 1st 
January 2005 up to the end of January 2016 was carried out using three electronic databases 
(Web of Science (PubMed), Ovid SP Medline and CINAHL via Ebsco). Included in the review 
were quantitative, qualitative and mixed-method studies. Reference lists of relevant papers 
were also hand searched. From the 983 papers identified, 46 papers were included. Quality 
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assessment was undertaken using the Mixed Methods Appraisal Tool and thematic analysis 
was used to analyse the data.  
Outcomes: From the analysis, six key themes with 15 sub-themes emerged: 1) fertility 
information provision (lack of information, timing of the information, patient-provider 
communication); 2) fear concerning the perceived risks associated with pursuing FP (delaying 
cancer treatment, aggravating a hormone positive cancer, consequences of a future 
pregnancy); 3) non-referral from oncology (personal situation, having a hormone positive 
cancer, not a priority, transition between service issues); 4) the dilemma (in survival mode, 
whether to prioritise one treatment over another); 5) personal situation (parity, relationship 
status); and 6) costs (financial concerns).  
Wider implications: This review has found that a wide range of internal and external factors 
impact the FP decision-making process.  Key external issues related to current service delivery 
such as the provision and timing of FP information, and lack of referral from oncology to the 
fertility clinic. However, internal issues such as women’s fears concerning the perceived risks 
associated with pursuing FP also hindered decision-making but these ‘risks’ were typically 
overestimated and non-evidence based. These findings suggest that the implementation of a 
range of decision support interventions may be of benefit within the clinical care pathway of 
FP and cancer. Women would benefit from the provision of more evidence-based FP 
information, ideally received at cancer diagnosis, in advance of seeing a fertility specialist, for 
example through the implementation of patient decision aids. Health care professionals in 
both oncology and fertility services may also benefit from the implementation of training 
programs and educational tools targeted at improving the communication skills needed to 
improve collaborative decision-making and deliver care that is patient-centred. Exploration 
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of the current barriers, both intellectual and practical, that prevent some patients from 
accepting FP will help care providers to do better for their patients in the future. Finally, the 
extent to which a poor prognosis and moral, ethical and religious beliefs influence the FP 
decision-making process also warrant further research. 
 
Key words: females, cancer, fertility preservation, decision-making, oncofertility, narrative 
review.  
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Introduction 
Treatments for cancer including chemotherapy, radiotherapy, hormonal, medical and surgical 
interventions may all affect female fertility. Loss of fertility is considered one of the most 
significant late-effects of cancer treatment (Mancini et al, 2008) and female cancer survivors 
often report it as one of the most distressing outcomes of their cancer treatment (Peate et al, 
2009).  
In the initial stages of treatment for cancer, the American Society of Clinical Oncology and the 
American Society of Reproductive Medicine recommends that options to preserve fertility are 
discussed with each woman (Lee et al, 2006; The Ethics Committee of the American Society 
of Reproductive Medicine, 2005). Similar guidelines have been published in the UK (NICE, 
2004; 2013). Of the fertility preservation (FP) options that are available for women, the most 
well-established is embryo cryopreservation. However, in order to create embryos it is 
necessary to unite an oocyte and sperm. Many young women facing cancer treatment are not 
at a point in their lives at which this is feasible, as they are not in a long-term relationship 
(Ajala et al, 2010). In addition, for religious and or ethical reasons, some women have 
objections to embryo cryopreservation (Lee et al, 2006).  
Another option is oocyte cryopreservation. Historically, this has not been successful due to 
inefficient methods for oocyte cryopreservation (Tao et al, 2008). However, use of vitrification 
has greatly improved survival of oocytes after freeze-thawing, giving women a better 
opportunity for FP without the need for fertilisation of the oocyte at time of collection.   
Ovarian tissue cryopreservation and subsequent regrafting has also now emerged as a 
realistic option for FP for women and girls who are not able to undergo ovarian stimulation 
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for oocyte or embryo cryostorage. There are also a number of cancer-specific fertility-sparing 
procedures including trachelectomy, ovarian transposition and ovarian shielding, but these 
are only suitable for women with specific cancer types or those undergoing pelvic 
radiotherapy.  
The past 40 years has seen changes in the ideology and practice of medical decision making.  
Models of doctor-patient decision-making have shifted from a ‘paternalistic’ approach, which 
sees health professionals as the gatekeepers of medical information and sole decision-makers 
and patients as passive spectators of care. With the growing recognition that patients 
(including cancer patients) expect to participate and be involved in their treatment decisions 
(Breitsameter, 2010; Siminoff et al, 2010), attention has therefore turned to the significance 
of patient-centred care and a shared model of decision-making, as a quality benchmark for 
the delivery of dignified care (Coulter and Collins, 2011; Department of Health, 2010; NICE, 
2014).  
However, despite the evolving health care climate and growing FP options available to 
women, the existing evidence suggests that women do not feel well supported in making 
these decisions, with many patients missing out on fertility care at this crucial time (Breast 
Cancer Care, 2014). These decisions are time-pressured and stressful, as women are having 
to trade-off the immediate consequences of starting cancer treatment with the longer-term 
chances of having a biological child in the future, post cancer treatment. The choice made will 
have a life-long impact (Kirkman et al, 2014). Typically, women also have to make decisions 
regarding FP with specialist fertility services alongside planning care for their treatment of 
cancer with oncology/haematology services. This necessitates transitioning between very 
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different medical services during the course of their cancer and fertility treatment and 
management (Lee et al, 2006). 
There are a range of studies and reviews that examine the barriers and facilitators that 
influence engagement in FP care from the perspective of the patient/ family and healthcare 
professional. These have made valuable contributions to our understanding of patients 
experiences of FP and the factors that may hinder decision–making generally (Kissil and 
Davey, 2011; McDowell and Murray, 2013; Nachtigill et al, 2006; The Ethics Committee for 
American Society of Reproductive Medicine, 2015). Specifically, fifteen published reviews 
have explored FP and decision-making for women with cancer (Dow et al, 2004; Goossens et 
al, 2014; Goncalves et al, 2014; Holton et al, 2014; Howard-Anderson et al, 2012; Jensen et 
al, 2011; Loren et al, 2013; Peate et al, 2009; Quinn et al, 2011; Schmidt et al, 2016; Sobota 
and Ozakinci, 2014; Penrose et al, 2012; Tschudin and Bitzer 2009; Zdenkowski et al, 2016; 
Lee et al, 2010). Although they have all made important contributions to the literature at the 
time they were produced, none of them examine solely and specifically the decision-making 
process around FP for women with a diagnosis of any cancer, leaving a gap in the knowledge 
base. 
Of the above reviews, six reported only on data from breast cancer patients (Dow et al, 2004; 
Goncalves et al, 2014; Howard-Anderson et al, 2012; Lee et al, 2010; Peate et al, 2009; 
Zdenkowski et al, 2016), thereby excluding information on women with many other different 
types of cancer contemplating FP. In addition, the review by Zdenkowski et al (2016) 
particularly focused on patient decision aids (PtDAs) for women with early stage breast cancer 
with only two PtDAs on FP included. Six reviews (Goossens et al, 2014; Jensen et al, 2011; 
Loren et al, 2013; Quinn et al, 2011; Tschudin and Bitzer 2009; Schmidt et al, 2014) included 
 
 
 9 
studies with mixed male and female participants or male-only studies. The review by Quinn 
(2011) was mainly focused on adolescents, including papers with participants aged between 
12 – 18 years. One review (Penrose et al, 2012) compared the psycho-social impact of 
treatment-related potential infertility on women with a cancer diagnosis, compared to 
women without cancer but facing infertility.  A review by Sobota and Ozakinci (2014) excluded 
qualitative studies. The final review (Holton et al, 2014) included studies examining the child-
bearing and related information needs of women with cancer as well as a range of other 
chronic, non-communicable health conditions. More detail on the existing reviews and their 
contribution to knowledge in this field is provided in Table 1. 
Defining the narrative review question 
The aim of this paper was to build upon the existing knowledge and evidence base and 
undertake a narrative review to examine solely women with any type of cancer, of 
reproductive age, and facing fertility-impacting treatment, for their associated decision-
making processes. Therefore, the question underpinning the narrative review was defined as 
“What factors hinder the decision-making process for women with any cancer and 
contemplating FP treatment?”. Our objectives were to i) assess and summarise this existing 
literature, ii) identify the factors that hinder this decision-making process, iii) explore to what 
extent these factors may differ for women choosing different methods of FP, and iv) make 
recommendations for future research and service delivery that may improve and better 
support women with cancer to make these FP decisions. 
Methods 
Searching for studies 
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From the 1st January 2005 up to the 31st January 2016, three electronic databases were 
systematically searched by two members of the research team (JH and ES): Web of Science 
(PubMed), Ovid SP Medline and CINAHL via Ebsco. In 2004, NICE guidelines for clinical practice 
made specific cancer and fertility recommendations for the first time: that “fertility 
preservation should be offered to all patients with cancer for whom it would be relevant” 
(NICE 2004). As a result, a search date of 1st January 2005 was chosen to synthesise evidence 
in the light of this change in clinical practice guidelines. The search terms used were (FP OR 
Cryopreservation OR Fertility OR Infertility) AND (Cancer OR Carcinoma OR Neoplasm OR 
Oncolog* OR Tumour) AND (Decision Making OR Qualitative OR Quantitative). Test searches 
were also carried out; one to determine whether the spelling of tumour would affect results 
(it did not). Reference lists of relevant papers were also hand searched by JH. Abstracts were 
also examined in order to determine whether fertility was discussed in relation to a diagnosis 
of cancer. 
 Inclusion and exclusion criteria 
As this review aimed to include the fullest range of methodologies, quantitative, qualitative 
and mixed-method studies were included. To enable a broad and comprehensive overview of 
the current literature, articles were included even if FP was only a minor theme in the article, 
and not the main topic.  
Our target population was adult women aged 16 years or more at the time data was collected 
on them by their respective study authors. Our rationale for limiting the review to women 
aged 16 years or more was because typically women aged younger than 16 years follow 
different clinical pathways i.e. they are often first seen in paediatric settings. Paediatric care 
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pathways are different and these young patients do not have the options for FP that are 
available to older mature women. Oocyte or embryo freezing procedures require vaginal 
scanning, which is not typically acceptable in patients less than 16 years. For this population, 
ovarian tissue cryopreservation is becoming a possible option. Although the sample of 
patients in the studies selected had to be 16 years or older at the time of their data collection, 
because of the retrospective nature of most of the studies (i.e. they were survivors of 
childhood cancer), this meant that some of the women were under 16 years when they 
received their cancer diagnosis.  
The papers selected could include samples of patients with any cancer grade, treated with 
curative intent, and at any stage of the cancer trajectory (i.e. diagnosis, treatment, post 
treatment).  Articles were excluded if they i) referred to decision-making and FP in the context 
of males only, ii) referred to decision-making in the context of pregnancy decision-making and 
late-effects concerns rather than FP specifically, iii) included a target population which had 
only non-cancer diseases affecting fertility, iv) were a news article, review, opinion piece, 
commentary, chapter of a thesis or book or only investigated the prevalence, medical or 
clinical aspects of female cancer and FP, v) were written in a foreign language as funding for 
translation services was not available, or vi) referred to decision-making and FP from the 
perspective of health care professionals only.  Papers examining both male and female 
fertility issues were retained if females were reported separately. Similarly, papers that 
included a mix of cancer and non-cancer diseases were also included if the data for the cancer 
sample were reported separately. Papers exclusively investigating the medical or clinical 
features of treatment for infertility in relation to cancer were excluded. 
Screening for studies 
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Two authors (JH and ES) independently reviewed the citations generated by the search, 
removing duplicates and those publication types deemed ineligible. Following this, abstracts 
were screened and the full text version of relevant papers were retrieved for further 
assessment (JH and ES). A sample of reports were reviewed by GJ and NM to ensure that the 
selection was consistent with the aims of the review and the inclusion and exclusion criteria. 
Any doubts regarding the inclusion of papers were resolved by consensus between the 
authors after discussion. 
Quality assessment  
The Mixed Methods Appraisal Tool (MMAT) which has been designed to appraise and 
describe the methodological quality of systematic reviews that include qualitative, 
quantitative and mixed-methods papers was applied to full text papers (Pluye et al, 2011). 
Given the mix of study designs included in the review, the MMAT was felt to be an appropriate 
tool in which to appraise the quality of papers across the study design methodologies. The 
quality of the papers can range from 0% to 100% (100% indicates highest quality) and was 
calculated using four criteria (Table 2). For qualitative and quantitative studies, each criteria 
met is 25%, for example, if all four criteria are met the score will be 100%. For mixed methods 
studies, the scores of the qualitative and quantitative components are combined, with the 
overall quality score being the lowest score of the study components. 
Three authors (GJ, JH and NM) quality assured the papers and discussed the information 
extracted to ensure agreement over the themes was reached.   
Data extraction 
 
 
 13 
A data extraction table was developed and applied to each of the selected papers, that met 
the inclusion criteria and quality assessment criteria, using a standard format (authors, year, 
country, approach, design, method, sample and setting, measures, results and summary).  
Data synthesis 
A process of systematic, thematic analysis and coding of the extracted data was conducted 
according to the standard principles of thematic analysis (Braun and Clark, 2006). Three 
authors (GJ, JH and ES) developed textual descriptions, which were tabulated in the data 
extraction summary form and developed a preliminary list of descriptive themes to identify 
the main, recurrent, and/or most important themes and/or concepts across multiple studies. 
A process of iterative discussion then took place between the authors to generate conceptual 
themes that helped to explain the phenomena being described in the literature, constantly 
comparing the themes being developed against the data. All three authors engaged in 
continual dialog to help reach a consensus on the themes identified. 
Results  
The database search produced 983 papers (Figure 1). After the initial round of screening the 
duplicates (n=430), a total of 553 paper were screened against title and abstract. A total of 
398 ineligible documents, articles in other languages and irrelevant articles were removed. 
Existing published review articles (n=15) were also separated out at this stage, to be evaluated 
for potential overlap (as reported in the introduction).  A total of 140 articles remained, which 
were then screened by abstract and full text. At this stage, 94 papers did not meet the 
inclusion criteria and four papers, assessing oncologists attitudes to FP rather than those of 
patients were also separated out to be examined independently (as reported in the 
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discussion) (Adams et al, 2013; Duffy et al, 2012; Forman et al, 2010; Shimizu et al, 2012). A 
total of 42 papers then met the inclusion criteria. A hand-search through the 42 papers’ 
references produced four additional articles, resulting in a total of 46 articles included in the 
review. One of these studies retrieved manually from the relevant paper references was 
outside of the ten-year time limit (Thewes et al, 2003) but was kept in because it was 
considered very relevant to the review. Nothing else was identified as relevant from the 
reference lists of the reviews that could have been included prior to our start date. 
The MMAT appraisal tool was used to assess the quality of the studies. The papers reviewed 
used four methodologies:  quantitative descriptive studies (n=17), quantitative non-
randomised designs (n=2), qualitative study designs (n=21), and mixed methods studies 
(n=6).  Quality varied across the papers and within methodologies but a majority of papers 
scored 75% and/or 100% (n=34). Nine papers scored 50% and three papers scored below 50% 
(Table 2).  
The majority of qualitative studies did not outline their use of reflexive practice, one of the 
four key scoring criteria for the MMAT, so few studies were able to score 100% for quality. 
Lower scoring papers were re-assessed.  For the purpose of the review, no papers were 
excluded based on methodological quality as it was felt that all studies contained information 
that was of value. 
Characteristics of the selected studies 
Table 3 outlines the study demographic details of the 46 articles, in which 19 papers were 
quantitative, 21 papers used a qualitative methodology and six papers used a mixed-methods 
approach.  Whilst the 46 papers reflected an international interest, the majority (n=18) 
 
 
 15 
originated from the U.S.A, nine studies were Australian, six were from the UK, four were from 
the Netherlands three studies were multi-national, whilst Sweden and Canada produced two 
studies each and France and Turkey reported one study each.  
Only a few studies cited the exact method of FP chosen. Of these, the sample mainly included 
women choosing either oocyte and/or embryo freezing. Only one study included a sample of 
women who chose ovarian tissue freezing (Klock et al, 2009) or ovarian suppression (Hill et 
al, 2012), although the sample was very small in both studies (n=2). 
About half of the studies (49%) reported on FP decision-making issues only in women with 
breast cancer and these patients were also the majority group in most of the other studies 
which described a more diverse sample of cancer patients.  
Evaluating the age range of the women included in the studies was difficult because in some 
studies, it was not mentioned or was not clear whether the stated patients’ age referred to 
the age at cancer diagnosis or the age at which they entered into the study. In addition, one 
study did not report the age range or mean age of their sample (Klock et al, 2009), and another 
simply reported that their patients were younger than < 50 years without providing further 
information (Vadaparampil et al, 2012). Most studies reported only the age range of the study 
participants without citing the mean age of the sample. Whilst the majority of studies 
included women “of reproductive age”, only four studies included women from age 16 
(Bastings et al, 2014; Baysal et al, 2015; Crawshaw et al, 2009; Peddie et al, 2012) and two 
studies included childhood cancer survivors aged between 7 and 21 years (Kim and 
Mersereau, 2015), and approximately 14 years or more at diagnosis (Wilkes et al, 2010), 
although they were all aged over 16 years old at the time of data collection.  
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Sample sizes and study design  
Sample sizes varied across the studies and also within the methodologies.   Qualitative studies 
generally have small sample sizes and the majority of such papers in our review (16 out of 21) 
recruited less than 30 participants.  Two studies (Corney et al, 2014; Kirkman et al, 2014) both 
recruited only ten participants but only included breast cancer patients.  Whilst Niemask et 
al, (2012) described theirs as a qualitative study, they recruited a total of 697 participants 
across a wide range of cancer types and conducted a survey which included only one open-
ended question. Quantitative studies were larger, with an average of 198 participants over 19 
studies.  The largest study, a postal survey (Letourneau et al, 2012) recruited 918 participants 
with a large range of cancer diagnoses.  Conversely, Peate et al, (2011) reported a sample size 
of 17, but the study was limited to breast cancer patients only. Six studies out of the 46 in this 
review used a mixed-methods study design.  The majority of these studies used both semi-
structured interviews combined with surveys. Gorman et al, (2014), however used focus 
groups and a web-survey in the research design.  
All the studies, except three (Balthazaar et al, 2011; Peate et al, 2011, 2012), were 
retrospective in design. It was difficult or impossible to determine for some of the studies 
how many years post-diagnosis and treatment some of the women in the studies were when 
they were surveyed and/or interviewed, as some papers did not report this information 
specifically (Garvelink et al, 2013; Klock et al, 2009; Mathur et al, 2013; Yee et al, 2012). 
Reported time frames varied up to 11 years post-diagnosis (Crawshaw et al, 2009) with an 
average of 9.5 years post-diagnosis (Neimasik et al, 2012). Most studies acknowledged the 
possibility of recall bias as a potential weakness in their design.  
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What factors hinder the decision-making process? 
Six key themes and 15 sub-themes which hindered FP decision-making emerged from the 
analysis (Table 4):  1) fertility information provision (lack of information, timing of the 
information, patient-provider communication); 2) fears concerning the perceived risks 
associated with pursuing FP (delaying cancer treatment, aggravating a hormone positive 
cancer, consequences of a future pregnancy); 3) non-referral from oncology (due to personal 
situation, having a hormone positive cancer, FP not being a priority, transition between 
service issues); 4) the dilemma (in survival mode, whether to prioritise one treatment over 
another); 5) personal status (parity and relationship status); and 6) costs (financial concerns). 
The findings of the review have been presented in terms of these six overarching themes 
along with their more detailed sub-themes below. A clinical flow chart has also been provided 
to demonstrate the key themes in relation to the cancer and FP pathway (Figure 2).  
Theme 1: Fertility Information Provision 
An over-riding theme identified in the review concerned fertility information provision, both 
in terms of the lack of written information provided to women, the time at which FP 
information was received, and patient-provider communication.  
Lack of information provision 
The majority (72%) of the research studies identified lack of information specific to oncology 
and FP as a major issue for this study population (Armuand et al, 2012, 2015; Balthazar et al, 
2012; Bastings et al, 2014; Baysal et al, 2015; Corney and Swinglehurst, 2014; Crawshaw et al, 
2009; Garvelink et al, 2013, 2013(b); Gorman et al, 2012, 2014; Hill et al, 2012; Karaoz et al, 
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2010; Kim and Mersereau, 2015; Jukkala et al, 2010; Lee et al, 2011; Lewis et al, 2013; Mancini 
et al, 2008; Mathur et al ,2013; Peate et al, 2011(b), 2012; Peddie et al, 2012; Penrose et al, 
2012; Perz et al, 2014; Partridge et al, 2004; Tschudin et al, 2010; Thewes et al 2003, 2005; 
Yee et al, 2012;  Vadaparampil et al, 2012; Wilkes et al 2010). Some papers specified a lack of 
written information (Armuand et al, 2012; Balthazar et al, 2011, 2012; Bastings et al, 2014; 
Corney and Swinglehurst, 2014; Garvelink et al, 2013, 2013(b); Hill et al, 2012; Jukkala et al 
,2010; Mathur et al, 2013; Wilkes et al, 2010; Yee et al,2012). However, overall, the majority 
of papers did not specify whether the lack of information provision was in terms of verbal or 
written information; and the retrospective nature of many of the studies meant it was often 
difficult to disentangle at which point in the care pathway information was lacking, although 
generally this related more to a problem within the oncology consultation.  
Interestingly, Armuand et al. (2012) reported that men were 14 times more likely to report 
receiving FP information compared with women. These findings have been supported by 
Armuand et al, (2015) in the qualitative literature, as only 4 out of 11 women reported  having 
received any communication about FP from their health care professionals. Similarly, 
Crawshaw et al. (2009) found that patients (teenagers and young adults) reported a negative 
impact, both at the time of diagnosis and afterwards, where they felt that FP information was 
considered to be inadequate and/or poorly delivered.  
Timing of information provision 
The timing of information provision was also seen as hindering the FP decision-making 
process.  There were 21 papers which reported that patients were not receiving FP 
information at the right time for them and this was a key factor affecting their decision-
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making (Balthazar et al, 2011; Corney et al, 2014; Corney and Swinglehurst, 2014; Crawshaw 
et al, 2009; Garvelink et al, 2013;  Gorman et al, 2012; Hershberger et al, 2013; Hill et al, 2012; 
Kirkman et al, 2014; Lee et al, 2011; Partridge et al, 2004; Peate et al 2011, 2011(b), 2012; 
Penrose et al, 2012; Perz et al, 2011; Thewes et al, 2003; Tschudin et al, 2010; Vadaparamil et 
al 2012; Wilkes et al, 2010; Yee et al, 2012,). It has been identified  that women with cancer 
should be given detailed information about fertility as early as possible (Corney et al, 2014), 
and that the optimal time for FP information is shortly after cancer diagnosis and during the 
treatment planning stage, specifically before the FP consultation appointment (Balthazar et 
al, 2011; Crawshaw et al, 2009; Garvelink et al, 2013; Hill et al, 2012; Kirkman et al, 2014; 
Peate et al 2011, 2011(b); Penrose et al, 2012; Partridge et al, 2004; Thewes et al, 2003; Yee 
et al, 2012, Vadaparamil et al 2012). For example, Vadaparampil et al (2012) concluded that 
missed clinical opportunities to provide FP information near the time of cancer diagnosis may 
impact long-term quality of life of the women. However, a grounded theory study of 38 male 
and female survivors of adolescent cancer found strong support for information provision 
about FP around diagnosis, regardless of gender, age, incapacity or availability of FP services 
(Crawshaw et al, 2009).  
Additionally, in support of these findings, four qualitative studies (Gorman et al, 2012; 
Hershberger et al, 2013; Lee et al, 2011; Wilkes et al, 2010) also reported that the ideal time 
for patients receiving FP was before the start of cancer treatment and up to one week after 
diagnosis (Lee et al, 2011). Gorman et al. (2012) also reported that although a discussion 
about fertility at the time of diagnosis was seen as difficult and overwhelming, breast cancer 
patients expressed a strong desire to be told about FP options before the start of cancer 
treatment. Hershberger et al. (2013) similarly concluded that women viewed receiving 
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information and education from clinicians as essential during the diagnosis and treatment 
planning stage.   
Other studies concluded that women needed to be given written FP information on multiple 
occasions, to enable them to re-visit information at different treatment stages (Corney and 
Swinglehurst, 2014; Hill et al, 2012; Perz et al, 2011; Tschudin et al, 2010). Optimal times 
specified included shortly after diagnosis, during treatment, at follow-up visits (Corney and 
Swinglehurst, 2014), and before and after the specialist FP consultation (Hill et al, 2012).   
Patient- provider communication 
A factor that appeared to hinder the decision-making process is related to dissatisfaction with 
the consultation and communication between the woman and her healthcare professional. 
The retrospective nature of many of the studies meant that it was often difficult to determine 
i) which member of the clinical team, or ii) to which consultation this referred. However, 
generally there appeared to be an unmet need whereby during consultations, women felt FP 
options were not discussed or clearly explained enough.  For example, Gorman et al. (2012) 
found that several participants discussed their disappointment that their doctors were 
hesitant to talk with them about fertility issues.  A third of the women in a study of African 
American breast cancer patients (Lewis et al, 2012) wanted additional emotional support at 
diagnosis. Some women reported that they felt too rushed to ask questions and initiate 
discussions during the consultations (Armuand et al, 2015; Bastings et al, 2014; Hill et al, 2012; 
Lee et al, 2011, Wilkes et al, 2010) which contributed to them feeling unsupported and 
generally neglected at this time (Wilkes et al, 2010).  The study found that having 
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unconditional trust in the clinician’s opinion contributed to women not feeling able to 
challenge or discuss FP if it was not mentioned during the consultation.  
Theme 2: Fear concerning the perceived risks of pursuing FP treatment  
Women’s fears concerning the perceived risks of pursuing FP treatment appeared to hinder 
the FP decision-making process. These fears mainly related to the risks associated with 
delaying cancer treatment, the possibility of aggravating a hormone positive cancer, and the 
potential consequences of a future pregnancy. 
Fear associated with delaying cancer treatment  
The fear associated with delaying cancer treatment related to both i) a perceived immediate 
threat that it may exacerbate the women’s current cancer status and ii) the perceived longer-
term threat of the cancer reoccurring (Crawshaw et al, 2009; Gorman et al, 2012; Kirkman et 
al, 2014; Klock et al, 2009; Lee et al, 2011; Wilkes et al, 2010). For example, in-depth 
interviews by Klock et al. (2014) reported that some breast cancer patients chose not to 
preserve fertility because of the fear that delaying chemotherapy might increase the chances 
of recurrence. In a UK qualitative study of teenagers and young adults, Crawshaw et al, (2009) 
reported that women who were offered oocyte freezing refused, primarily to avoid delay to 
treatment. Similarly, in another UK study, Lee et al. (2011) found that women with existing 
families felt they could not afford to jeopardise their current children’s quality of life by 
potentially denying them a mother if they delayed the start of cancer treatment. However, 
the study findings also revealed that women without children were more willing to take risks 
by delaying the start of chemotherapy to have fertility treatment.   
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Fear of aggravating a hormone positive cancer 
Two qualitative papers (Lee et al, 2011; Snyder and Tate, 2013) and one quantitative study 
(Klock et al, 2009) found hormone sensitivity to be a factor in the FP decision-making process, 
due to the fear of cancer returning For example, Lee et al. (2011) reported from focus group 
interviews that, unsurprisingly, the priority for most women with breast cancer was survival, 
and that ovarian stimulation was perceived to carry a significant risk to this and could affect 
recurrence rates. Similarly, in studies by Snyder and Tate (2013) and Klock et al. (2009), it was 
found that women with cancer feared taking the additional hormones needed for the banking 
of oocytes or embryos as this may elevate the likelihood of cancer recurrence and the fear of 
exacerbating their disease as a result of the ovarian stimulation. 
Fears associated with the consequences of a future pregnancy 
Also hindering the decision to accept FP were women’s fears associated with the 
consequences of a future pregnancy, post cancer treatment. This fear related to the woman 
themselves, particularly in terms of their own health status and cancer re-occurrence 
(Connell, et al 2006; Corney et al, 2014; Lee et al, 2011; Partridge et al, 2004; Wilkes et al, 
2010). However, the fear associated with the consequences of a future pregnancy also 
extended to any potential future child born as a result of their FP treatment (Canada and 
Schover, 2012; Corney and Swinglehurst, 2014; Gorman et al, 2012; Kirkman et al, 2014; 
Niemasik et al, 2012; Wilkes et al, 2010). This particularly related to genetic transmission and 
the future child’s own health, in terms of being more prone to cancer, but also possibly to 
other abnormalities (Corney and Swinglehurst, 2014; Niemasik et al 2012; Wilkes et al, 2010). 
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These concerns about genetics and family history were evident in women with or without any 
family history or genetic risks (Gorman et al, 2012).  
Theme 3:  Non-referral from oncology  
Other factors identified as hindering the decision-making process related to clinical barriers. 
These clinical barriers related to the women’s personal status, having a hormone positive 
cancer, FP being seen as not a priority, and problems with the service and/or transitions 
between services. 
Personal situation 
One reason that appeared to prevent a referral to fertility services was the woman’s personal 
status. Two qualitative semi-interview studies in the UK found that some child-free women 
who were also single felt that clinicians were less likely to consider FP for them (Corney et al, 
2014; Corney and Swinglehurst, 2014), possibly because success rates were felt to be lower 
with oocyte compared with embryo freezing (Corney and Swinglehurst, 2014). Peddie et al. 
(2012) also reported that some women who were without a long-term partner gained the 
impression from health professionals that they had little to gain and/or were unsuitable for 
cryopreservation of gametes and hence ruled out this possibility. 
However, conversely, for women who already had children, some women reported that 
health professionals had ruled out FP for them, under the assumption that they had already 
completed their families (Peddie et al, 2012). Similarly, Lee et al. (2011) explored focus group 
interview data to illustrate that women with breast cancer who already had children 
perceived that health professionals assumed they would not want further children and were 
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therefore they not given the option of FP. This finding has also been supported by Neimasik 
et al. (2012), who through the use of open-ended questions, found that 16% of women who 
had one or more children perceived that physicians projected less significance on future 
fertility.  
In some qualitative studies, women hypothesised that their age may have played a role in the 
lack of referral and discussion about FP, particularly if they were seen as too old and therefore 
had completed their family (Armuand et al, 2015). In an earlier study, Armuand et al. (2012) 
found that women under 35 years with no children were significantly more likely to receive 
FP information. However, on the contrary, a study of teenage and young adult cancer patients 
reported that some women stated that their doctors wanted to postpone FP discussion with 
them until they were older (Gorman et al, 2012). Neimasik et al (2012) also found that some 
younger women reported that their age meant they were not referred for FP. 
Having a hormone positive cancer 
In relation to having a hormone sensitive cancer, Corney and Swinglehurst (2014) reported 
that four out of 19 women with breast cancer stated that the main reason for not being freely 
given the option of FP was having a hormone-sensitive cancer. Patients in a study by Niemasik 
et al. (2012) reported that their physicians cited risk of cancer recurrence in hormone 
sensitive cancers as a reason not to preserve fertility.  
FP not a priority 
A contributing factor which appeared to hinder the decision-making process for women was 
the perception that their healthcare professionals considered fertility issues a low priority 
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compared to starting cancer treatment and survival (Corney et al, 2014; Corney and 
Swinglehurst, 2014; Gorman et al, 2012; Thewes et al, 2003; Wilkes et al, 2010). For example, 
Thewes et al, (2003) and Wilkes et al, (2010) reported from focus groups and interview data 
that some women often felt there was a discord between their perceived importance of 
fertility and the importance their doctors attributed to it.  
Other problems with the service/ transition between services 
Women with cancer have to make time-pressured decisions regarding FP with specialist 
fertility services whilst undergoing treatment of their cancer with oncology services. Problems 
with service delivery and transitioning between these two services also hindered the FP 
decision. Long waiting times to see a fertility specialist and appointment delays until after 
chemotherapy had been arranged were reported by Corney and Swinglehurst (2014).  In 
addition, Garvelink et al, (2013) reported that women wanted improved communication 
between treatment centres.  Some women stated that information provision was delayed, 
resulting in either late oncology appointments or late referrals to FP services. Several 
participants in a study by Gorman et al. (2012) perceived that poor co-ordination of care 
between different medical centres was a problem for young adult cancer patients. Similarly, 
participants in a study by Mathur et al. (2013) felt they were being pushed from provider to 
provider with no-one helping them to make decisions. Yee et al. (2012) also reported that 
some patients stated there was a delay in getting an FP referral due to seeing different 
medical consultants.  
Theme 4: The dilemma  
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A dilemma appeared to take place for women, which played an important role in hindering 
FP decision-making. The dilemma for women related to choosing to be in survival mode and 
whether to prioritise one treatment over another with the ‘double whammy’. 
In survival mode 
Many patients reported survival as their primary focus and as an important factor in their 
decision not to pursue FP (Crawshaw et al, 2009; Lee et al, 2011; Garvelink et al, 2013), and 
that cancer treatment was a priority over future fertility (Hershberger et al, 2013, 2016; 
Kirkman et al, 2014; Mathur et al, 2013; Penrose et al, 2012; Perz et al, 2014; Snyder and Tate, 
2013; Thewes et al, 2003; Wilkes et al, 2010). For example, Penrose et al. (2012) explored this 
issue during interviews with both women and men with various cancer types, and reported 
that 28% of patients stated that they were in “survival mode” at diagnosis and were focussed 
on treatment options that would maximize their chances of survival.  
Whether to prioritise one treatment over another and the ‘double whammy’ 
For many women, the emotional impact of deciding between two different treatments and 
the consequences associated with these appeared to hinder the FP decision (Armaund et al, 
2015; Corney and Swinglehurst, 2014; Hershberger et al, 2013, 2016; Kirkman et al, 2014; 
Mathur et al, 2013; Perz et al, 2014; Snyder and Tate, 2013). For example, in one qualitative 
study, patients described how they did not ask questions about their risk of fertility or tried 
to avoid thinking about or discussing the risks of infertility associated with their cancer 
treatment as the emotional impact would be too great (Armaund et al, 2015). Snyder and 
Tate (2013) also reported some respondents describing an intense emotional experience of 
having to make FP decisions while grappling with a potentially life-threatening experience. 
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Similar findings were reported by Corney and Swinglehurst (2014), with women also reporting 
a lack of emotional support to guide them through these decision dilemmas. Further 
interview studies by Mathur et al. (2013) and Kirkman et al. (2014) also identified that some 
women found the initial diagnosis so overwhelming they could not consider fertility, feeling 
that they were forced to make a choice between the two.  
Deciding between the two treatments was sometimes described as a “double-trauma” (Perz 
et al, 2014). Interview data from Hershberger et al. (2013) also outlined a similar “double-hit” 
scenario with breast cancer and possible infertility seen as two blows. In a later paper by 
Hershberger et al. (2016), four women who declined treatment reported that the mental and 
physical energy needed to engage in FP treatment was beyond their capabilities. 
Theme 5: Personal Status 
Women’s personal status, in terms of both parity and relationship status, appeared to 
influence the FP decision-making process.  
Parity  
Seven papers reported a difference in how patients viewed and accessed the treatment 
options offered to them, based on whether they had existing children or not (Armuand et al, 
2012; Canada and Schover, 2012; Kirkman et al, 2014; Lee et al, 2011; Letourneau et al, 2012; 
Niemasik et al, 2012; Mersereau et al, 2013). Overall, across these papers, findings revealed 
that already having children appeared to reduce interest in FP. For example, a quantitative 
survey found that women with children were less likely to take action to preserve their fertility 
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than women without children (Letourneau et al, 2012) and were also less likely to receive 
information about FP (Armuand et al, 2012).  
Relationship status 
The other personal factor which appeared to be a barrier to FP was relationship status and, 
in particular, being single (Baysal et al, 2015; Corney et al, 2014; Corney and Swinglehurst 
2014; Hershberger et al, 2013, 2016; Gorman et al, 2012; Mersereau et al, 2013; Synder and 
Tate, 2013, Wilkes et al, 2010). Hershberger et al (2013, 2016) reported that an additional 
burden for single women in their decision-making was having to approach partners, about 
whose long term commitment they were unsure, to discuss FP. Also attending fertility clinics 
as a single woman was perceived as difficult because the majority of those attending were 
young couples (Corney et al, 2014). One qualitative study found that being single was a barrier 
to FP simply because they were too young to have a partner and not ready to have or even 
think about children (Wilkes et al, 2010).   
Two qualitative studies further explored the impact of relationship status on FP choice and 
found that women in a stable relationship overall favoured embryo cryopreservation because 
the fertility outcomes were better with cryopreservation of embryos than with oocytes, 
whereas for single women oocyte cryopreservation was the only option unless a sperm donor 
could be found, which was not a realistic option in the short time available before start of 
treatment (Corney et al, 2014; Corney and Swinglehurst, 2014). 
Theme 6: Costs 
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A factor identified as hindering the FP decision-making process related to financial concerns. 
The cost of FP appeared to play a key constraining factor in the decision whether to access 
FP. 
Financial concerns 
The cost of FP, and the implied effect this has on the decision-making process, was reported 
as an influential factor in eleven papers (Balthazar, 2012; Hershberger et al, 2013, 2016; 
Gorman et al, 2012; Hill et al, 2012; Kim et al, 2013; Klock et al, 2009; Mathur et al, 2013; 
Mersereau et al, 2013; Snyder and Tate, 2013; Yee et al, 2012). Of the papers identified, the 
issue of cost was deemed to be one of the major constraining factors in accessing FP, and 
three papers identified cost as the most influential factor impacting upon the decision-making 
process (Balthazar et al, 2012; Gorman et al, 2012; Hill et al, 2012). However, eight of the 
eleven studies were from the U.S.A, where fertility health care costs are significant and not 
routinely covered by insurance. Web-based survey findings have also reported that decisional 
conflict was higher in those patients who reported that cost was strongly influential in the 
treatment decision (Kim et al, 2013).  This was confirmed by Mersereau et al. (2013) who 
employed a similar web-based survey, and reported that patients for whom the costs of FP 
were prohibitive reported higher decisional conflict scores using the Decisional Conflict Scale. 
The study further demonstrated that women who were not referred for FP counselling, or 
who were unable to afford the cost of fertility treatment, experienced a significant increase 
in levels of decisional conflict.   
Discussion  
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The aim of this review was to build upon the existing evidence base and identify the factors 
that hinder the FP decision-making process for women with any cancer and, in doing so, 
identify the ways that service delivery can be better improved to support patients.  
From our review, a range of diverse external and internal factors were identified. Most of the 
factors which hindered the process related to service delivery issues and external factors 
beyond the patients control, such as the provision and timing of FP information and a lack of 
clear referral pathways from oncology to the fertility clinic. Internal psychological factors such 
as women’s fears concerning the perceived risks associated with pursuing FP also played a 
role. Some of these risk perceptions appear to be over-estimated and non-evidence based. It 
was also evident that the combination of a diagnosis of cancer and having to contemplate 
future infertility has a long-lasting and significant impact on women’s lives.  This was shown 
by a range of quantitative indicators such as quality of life and decisional conflict as well as by 
the detailed narratives of patients captured in the qualitative research studies reviewed.   
In agreement with the findings of many of the articles and reviews to date in the area, our 
review reinforces a clear need for more specific and targeted information provision, both at 
the time of cancer diagnosis/treatment planning and most importantly, before the fertility 
consultation, which would better prepare and support women making decisions about their 
future fertility. Lack of information from the patient’s perspective appears important because 
low levels of fertility-related knowledge has been linked to increased decisional conflict in 
young patients with breast cancer (Peate et al, 2011b) and a perceived lack of overall support 
for women (Bastings et al, 2014).  
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The implementation of patient decision aids may be one way of addressing this issue. PtDAs 
are one type of decision support intervention. They are information resources supporting 
people to make decisions between healthcare options (Stacey et al, 2011). They are evidence-
based resources, drawing on clinical effectiveness of healthcare options data, studies of 
patients’ decision-making and illness experiences, and evidence from the decision sciences 
on how people make healthcare choices (Bekker et al, 2013). PtDAs support people to make 
reasoned decisions, i.e. ones based on accurate information about the consequences of all 
options, in accordance with their beliefs and trade-offs between their treatment preferences 
(Rothert et al, 1977, O’Connor and Edwards; 2001, Bekker et al, 1999). Whilst there are many 
FP resources publically available for women with cancer, few exist to support the FP decision 
process in women of reproductive age (Mahmoodi et al, 2016). To our knowledge, only two 
PtDAs have been designed for women with breast cancer specifically, one in Australia and the 
other one in the Netherlands (Peate et al, 2011; Garvelink et al, 2013b). For example, there 
are currently no PtDAs available for women in the UK, although one is in the early stages of 
development and testing (Jones et al, 2017).  
Effectiveness studies of these two PtDAs suggests that they may better support women to 
make FP decisions. The PtDA booklet of Peate et al. (2012), has been found to reduce 
decisional conflict and regret with the decision made, and increase knowledge about FP for 
breast cancer patients, and the Dutch evidence-based web-based PtDA about FP for women 
with breast cancer has been found to improve information provision in the Netherlands and 
increase knowledge about FP for breast cancer patients (Garvelink et al, 2014).  To our 
knowledge, no other trials have been conducted to explore the effectiveness of PtDAs within 
the context of FP and cancer.  
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It is possible therefore, that a new PtDA for women with any cancer, that can be administered 
both at the time of diagnosis/cancer treatment planning stage in the oncology clinic before 
they see a fertility specialist, may be of value. In particular, the value would relate to the 
provision and timing of evidence based information (Theme 1), addressing some of the fears 
concerning the perceived risks of pursuing FP treatment (Theme 2) and the ‘dilemma’ of 
whether to prioritise one treatment over another (Theme 4). However, it is important that 
the development of any future new PtDA is not just a practical exercise but also makes explicit 
the use of decision theory during its development. A number of normative and descriptive 
decisions theories exist (Elwyn et al, 2010). To ensure that the theory-practice gap is 
addressed in relation the development of PtDAs and other decision support interventions, 
using theoretical frameworks to inform development is recommended (Elywn et al, 2010). 
Based upon the findings of this review, the authors are currently developing a new FP PtDA, 
for women aged 16 years or over with any cancer, and aim to follow this guidance for the 
integration of decision-theory during its development (Jones et al, 2017). It will be interesting 
to see how well it fulfils these unmet needs for women during its acceptability and evaluation 
phases. 
Despite the wide variation in samples, sample size and research methodologies within the 
papers, overall, women seemed to have the same internal concerns which hindered the FP 
decision. Fear of recurrence was both a concern of women attempting to balance the need 
for survival with the need to delay treatment in order to preserve fertility and of the 
oncologists attempting to quantify the risk of different treatment regimens and timelines.   
Although most of the studies found that survival was seen as more important than preserving 
fertility, childless women may be more prepared to take a risk but conversely, oncologists 
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may be less willing to sacrifice survival for fertility than their patients.  There is some evidence 
that single women may experience more difficulties, both in accessing a fertility consultation 
as well as having less preservation options, and this may lead to long-lasting and persistent 
distress about child-bearing. Conversely, it is also reported that women with children either 
feel they cannot risk their long-term survival by preserving fertility or report that they 
perceive health professionals as less willing to refer them to fertility services.  
Linked to fears of recurrence, hormone receptor status is a significant factor hindering FP 
decision-making for women with breast cancer, the most common cancer in this review. For 
oncologists, this was also a consideration when deciding whether FP was feasible. However, 
several papers reported both patients and health professionals overestimated the risks 
associated with FP treatment generally.  Balthazar et al. (2011) found that only 17% of female 
patients with wide ranging cancer types knew that FP and pregnancy did not increase the risk 
of cancer recurrence. This is despite the fact that an association between increased risk of 
recurrence and pregnancy after cancer has not been identified and pregnancy may even have 
a protective effect (Blakely et al, 2004; Ives et al, 2007; Jeruss et al, 2009). 
Patients also over estimated their infertility risk (Partridge et al, 2004; Penrose et al, 2012).  
Partridge et al. (2004) found through use of global web-based surveys that a substantial 
proportion of women diagnosed with breast cancer overestimated their risk of becoming 
post-menopausal after treatment. Semi-structured interviews with both men and women 
revealed that 33% of participants assumed that treatment would definitely make them 
infertile (Penrose et al, 2012). Whilst all healthcare information should be evidence-based, it 
may be that by presenting the information within the context of a decision support 
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intervention (e.g. within a PtDA), may help reduce the risks perceived by women and support 
better decision-making. This evaluation is recommended for future research. 
We identified that external service delivery problems hindered the FP decision-making 
process. A recent paper, particularly in relation to the UK has also reported that current 
service delivery for women in this area is poor (Anderson and Davies, 2016). One particular 
issue highlighted in our review was in relation to the perceived lack of referral to fertility 
services from oncology and lack of FP discussions during the oncology consultation which 
women felt was based upon their personal situation e.g. age, relationship status, parity, the 
type of cancer they had (hormone positive) and the perception that oncologists placed much 
more weight on survival than on the late effect of possible infertility.  
Indeed, a recent study by Breast Cancer Care (2014) reported that more than a third of 
specialist breast cancer doctors and nurses surveyed said that they did not discuss the risk of 
treatment with young female breast cancer patients. Of these healthcare professionals, 26% 
also said that there was no clear system for directing patients to fertility clinics in the UK. If 
the findings of this survey reflect theexperiences of women across the country, the charity 
says indicated that about 5000 young breast cancer patients could be missing out on FP each 
year (Breast Cancer Care, 2014).  
Other research exploring the perspectives of oncologists supports the reasons for avoidance 
of discussion concerning FP by the oncologist and for non-referral of women to a fertility clinic 
(Adams et al, 2013; Duffy et al, 2012; Forman et al, 2010; Shimizu et al, 2012). One UK study 
of 100 oncologists (Adams et al, 2013) reported that 87% of oncologists expressed a need for 
more specialist FP information and only 38% of oncologists surveyed stated that they 
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routinely provided patients with written FP information. Similar findings have been reported 
in the USA (Duffy et al, 2012; Forman et al, 2010). Duffy et al. (2012) reported that only 18% 
of 344 oncologists reported having specific FP information for patients. Only about half of 
respondents reported moderate or high confidence in their knowledge about FP options. 
Duffy et al. concluded that oncologists’ confidence in their knowledge regarding FP options in 
the study was “moderate at best”. In another paper, Shimizu et al. (2013) reported in a cross-
sectional survey with 843 Japanese breast cancer specialists, showing that physicians who had 
better knowledge and positive attitudes toward FP were more likely to discuss future fertility 
with patients and to make referrals to reproduction specialists.  
Therefore, from the existing literature, the need for more resources to support oncologists 
with the FP discussion and the multi-disciplinary teams involved in women’s care has been 
recommended and developed (Woodruff, 2014). At a minimum, it is of importance that 
healthcare providers have access to adequate training programs and up-to-date clinical 
guidelines so that they can be fully informed of oncofertility standards of care for this patient 
group (Johnson and Gracia, 2014). For example, the Oncofertility Consortium have developed 
a wide range of communication tools to support oncology and fertility healthcare 
professionals (LaBrecque et al, 2014).  
The findings from this review support these initiatives but also recommends that the 
implementation of any educational tools targeted at improving the communication skills are 
designed to improve collaborative decision-making and deliver care that is patient-centred. 
Given that one of the barriers to the FP decision identified from this review, related to 
‘transition with service issues’ between oncology and fertility services, one particularly 
exciting shared-decision model moves beyond the simple physician-patient dyad to 
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encompass the interdisciplinary teams involved in a patient’s care (Knowledge to Action) 
(Legare et al, 2011). Whilst the model was originally developed within primary care, toolkits 
embedded within this concept may offer real benefit to address the transition to service 
issues at a secondary care level, and more research to explore this is recommended.  
A three-step model to promote shared-decision-making within clinical practice has also been 
proposed. It focuses on ‘Choice talk’ (making sure the patient knows reasonable options are 
available), ‘Option talk’ (providing the patient with more detailed information about the 
options) and ‘Decision talk’ (supporting the patient to form preferences and make the best 
decision for them) (Elwyn et al, 2012). The model also includes the integration of PtDAs and 
providing training to healthcare professionals (particularly the oncology care team) in this 
model, supplemented by a PtDA, may help overcome many of the barriers to the FP decision 
identified from this review, and again this warrants further research and evaluation.  
Despite the different countries being compared, cost was cited as a factor which influences 
whether women decide to undergo FP. However, nine studies out of the eleven we identified 
which report cost as a factor originated from the USA where healthcare costs associated with 
FP can be prohibitive. The other two studies were carried out in Canada where health 
treatment costs are variable. For women in the UK diagnosed with cancer, NHS funding may 
be available, but the amount of funding and the criteria for treatment varies between Clinical 
Commissioning Groups (CCGs) and different regions.  As a consequence, equity of funding has 
been recommended for the UK (Anderson and Davies, 2016) and this change in service 
provision may help remove ‘cost’ as a factor hindering FP decision-making in the future. In 
the meantime, the provision of specific funding information, applicable to the treatment 
centre, early in the FP care pathway is recommended. 
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The main factor influencing the choice of fertility option, embryo versus oocyte 
cryopreservation, was relationship status. If women were in a relationship then embryo 
cryopreservation was overall the favoured choice, mainly because the odds were seen as 
better; and for single women, oocyte cryopreservation was regarded as the only option 
(Corney and Swinglehurst, 2014). Oocyte vitrification has dramatically improved the success 
of oocyte cryopreservation, enabling fertility preservation to be a promising option for these 
women. Another relatively new approach to preserving a woman’s fertility is ovarian tissue 
cryopreservation, in which the outer layer of an ovary, which contains a large number of 
immature oocytes, is collected laparoscopically and frozen for future use.  While still 
considered an experimental procedure, the approach is performed to preserve fertility for 
pre-pubertal girls, for women who need urgent treatment and hence do not have time to 
undergo ovarian stimulation and oocyte retrieval or for women who are advised not to use 
fertility drugs due to perceived risk with a hormone sensitive cancer. Although this new 
approach is currently not routinely available to all women with cancer in the UK, it could 
become the preferred option for many patients, particularly if it becomes possible to mature 
oocytes in vitro after collection from the tissue sample. Ovarian tissue cryopreservation could 
be seen as less stressful than ovarian stimulation and oocyte retrieval for women, and could 
obviously be utilised regardless of relationship status, by women considering FP following a 
cancer diagnosis. 
One of the main reasons for pursing FP appeared to be the simple desire to ‘keep options 
open’ as a ‘back-up or ‘insurance’ plan (Mathur et al, 2013; Snyder and Tate, 2013) and 
therefore supporting more women with FP material and to have referral to a fertility clinic 
provides the opportunity for women to have these discussions (Armuand et al, 2015). This is 
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particularly important because even just being referred for a FP consultation has been shown 
to be associated with less decisional conflict in the future (Mersereau et al, 2013). Similarly, 
receiving counselling from both the oncology team and FP services appears to reduce 
decisional regret (Letourneau et al, 2012).  Therefore, ensuring patients have access to 
counselling is important. However, in the current literature, it appears (or is unclear) that the 
counselling has been carried out by the reproductive/oncology expert (Letourneau et al, 
2012; Bastings 2014; Neimisk, 2012) rather than a counsellor. It is recommended that women 
also have access to these trained professionals who are qualified to deliver psychological 
support, especially as a sub-theme generated from the review was a perceived lack of 
emotional support during the decision-making process.  
It is unclear to what extent moral, ethical and/or religious beliefs play a part in the decision-
making process, as this was only explicitly reported in one of the papers assessed in this 
review (Hershberger et al, 2016). This may reflect the predominately Caucasian origins of the 
women included in the research, or that women are not being asked specifically to what 
extent these issues played a role in their decision-making. More research to explore the ways 
in which ethnicity and/or religious beliefs influence the FP decision-making process would be 
valuable to ensure standardised care across minority groups. Oncologists have also cited poor 
prognosis as a reason for non-referral to the fertility clinic (Adams et al, 2013; Shimizu et al, 
2013; Duffy et al, 2012) but more research is needed to ascertain the ways in which this may 
hinder referral and FP decision-making from the oncologist and patient perspective.   
Strengths and Limitations  
We have attempted to synthesise and summarise the current body of knowledge on the 
factors which hinder FP decision-making by women with cancer of reproductive age and in 
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doing so, identify means for improvement of service delivery to better support female cancer 
patients. This narrative review has identified a large body of literature which encompasses a 
range of study methodologies, qualitative and quantitative and mixed methods, and has 
included studies of women with any cancer whilst recognising that most studies have been 
restricted to women with breast cancer. 
Whilst we attempted to undertake a comprehensive and systematic search, we are aware 
that our databases were mainly ‘health focused’ and therefore some papers may have been 
missed. We have used a thematic approach to assess and synthesise the information in the 
46 papers reviewed and to provide insights into the FP decision-making process.  We have 
not reported qualitative and quantitative studies separately but rather have used an 
aggregative synthesis approach to summarise with a narrative review of the evidence (Dixon-
Woods et al, 2006).  
The studies were heterogeneous, with a wide variety of inclusion criteria.  Some included men 
and women, diseases other than cancer, differing outcome measures and study designs. A 
limitation is that the literature to date has primarily been focused on women choosing 
whether to choose fertility preservation or not, rather than either oocyte or embryo freezing, 
or didn’t specifically report the methods of FP in the study. Overall, the quality of papers was 
good, but the current evidence base is limited by a lack of prospective studies, and the paucity 
of data collected and reported on cancer populations outside of women with breast cancer. 
For these reasons, there was insufficient evidence to appraise whether there were differences 
in factors affecting women´s decisions according to their cancer diagnosis or by FP technique. 
Many of the studies had small sample sizes but this is to be expected within this field of 
research.  
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Conclusions and implications for future research 
In conclusion, a number of interventions may be useful in addressing the wide range of 
internal and external factors that impact on the FP decision-making process (e.g. the 
implementation of PtDAs, education resources to improve communication and patient-
centred care, referrals to trained FP counsellors within both oncology and fertility services 
and simply ensuring there is time to have the FP discussion during the oncology consultation) 
but it is unlikely that one intervention alone will remove all the barriers for these women 
identified from the review. It is recommended that the development/implementation of any 
such decision support interventions are grounded within a theoretical shared-decision 
framework to help bridge the theory-practice gap within the decision-making field. 
To continue to extend recommendations for service delivery, more research is needed to 
explore further how best to facilitate decision-making in the context of technologies other 
than oocyte and embryo freezing. Exploration of the current barriers, both psycho-social and 
practical, that prevent some patients from accepting FP will also help care providers to do 
better for their patients in the future. Finally, the extent to which a poor prognosis, and moral, 
ethical and religious beliefs influence the FP decision-making process also warrants further 
research. 
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